Plain-English translation of NCT07483450 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called in people who have been diagnosed with either relapsing multiple sclerosis (where symptoms come and go) or primary progressive multiple sclerosis (where symptoms gradually worsen over time). The study will check whether the medication is effective and safe for Chinese patients, and will also measure how the treatment works in the body.
While this medication is already approved in some countries, this study will help ensure it works well and safely for Chinese patients specifically, and will give doctors a better understanding of how the treatment affects the immune system in people with these types of multiple sclerosis.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive intravenous infusions of the medication through an IV in your vein. For the first cycle, you'll receive two infusions two weeks apart; after that, you'll receive one infusion every 24 weeks (about 6 months). You'll have regular clinic visits for infusions, blood tests, and MRI scans to check how you're responding to the treatment. The study will last approximately 2 years, though the exact duration depends on which group you're in.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China